Study Selection
Eligible studies had to be 1) original investigations published in a
peer-reviewed journal before November 1, 2022; 2) include human patients
over 18 years old; 3) report an intervention as prophylaxis or treatment
for ototoxicity induced by any chemotherapy agent; 4) be published in
English; 5) use an experimental or quasi-experimental research design,
and 6) report treatment outcomes, either their safety or efficacy.
Ototoxicity induced by chemotherapy was considered as hearing loss,
tinnitus, or vestibular disturbances after chemotherapy treatment. Gray
literature, editorials, commentaries, case series with ten or fewer
patients, case studies, and protocols were excluded from the review.